Pre-Made Onfekafusp Alfa Biosimilar, Fusion Protein targeting FN/FN1 fused with human TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) - trimer: Recombinant therapeutic protein targeting CIG/ED-B/FINCZ/GFND/GFND2/LETS/MSF/SMDCFfor drug discovery and mechanism of action (MOA) research

Pre-Made Onfekafusp Alfa Biosimilar, Fusion Protein targeting FN/FN1 fused with human TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) – trimer: Recombinant therapeutic protein targeting CIG/ED-B/FINCZ/GFND/GFND2/LETS/MSF/SMDCFis a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

ED-B is predominantly expressed during angiogenesis and tumor growth. Onfekafusp Alfa is an immunocytokine consisting of human pro-inflammatory cytokine tumor necrosis factor alpha (TNFalpha) fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), with potential immunopotentiating and antineoplastic activities. L19 moiety of onfekafusp alfa binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the TNFalpha moiety may locally induce an immune response against ED-B fibronectin-expressing tumor cells and may specifically decrease the proliferation of ED-B-expressing tumor cells.